Acacia Research Corporation

Total revenue was $114.6 million, up from $51.2 million in the prior-year period. Total company adjusted EBITDA was $17.3 million, operated segment adjusted EBITDA was $22.8 million, and GAAP net income attributable to Acacia was $47,000, or $0.00 per diluted share; adjusted net income was $12.8 million, or $0.13 per diluted share. Segment revenue included Benchmark at $20.5 million, Deflecto at $27.1 million, Printronix at $6 million, and Intellectual Property licensing and related revenue at $60.9 million. The company ended with $334.6 million of cash, cash equivalents, equity securities measured at fair value and loans receivable, and no parent company debt; book value was $557 million, or $5.71 per share. Management did not provide formal next-quarter or full-year guidance on the call.

MJ McNulty framed the quarter as another example of disciplined capital allocation and diversified execution. He emphasized that Acacia is focused on compounding long-term intrinsic value per share, not maximizing near-term earnings, and said the company is evaluating a broad range of acquisition opportunities but will remain patient and selective. He also highlighted stronger IP monetization, active cost reduction in the platform, and encouraging regulatory progress at AMO Pharma, while reiterating that the Mycovia/VIVJOA investment was fully written down.

Michael Zambito said the quarter’s results reflected continued disciplined execution across the portfolio and the benefits of diversification. He cited $114.6 million of total revenue, $19.6 million of consolidated G&A expense, $8.5 million of operating income, and $17.3 million of adjusted EBITDA. He also pointed to $334.6 million of liquidity, no parent company debt, and total gross indebtedness of $90.4 million, consisting of $59.5 million at Benchmark and $30.9 million at Deflecto. He noted that book value declined slightly to $557 million from $567.2 million, with gains in operating income and the public equity portfolio offset by parent expenses and the MalinJ1 write-off.

Analysts focused on Benchmark well performance and whether additional wells could match the Cherokee well; management said the current quarter included a full period from the new well and that future wells are being underwritten to type curves similar to that performance. On Deflecto, management said trucking and OEM inventory trends are encouraging but the benefit has not yet fully shown up in results. On deal flow, McNulty said the pipeline is the strongest it has been, with particular interest in stressed situations tied to private credit and in bilateral private equity situations rather than auction processes. On the IP settlement, he said the $10.9 million IP EBITDA is not the best proxy for the TP-Link recovery, and the cash from that settlement was received in Q3 rather than included in the quarter-end cash balance.